BMS-911543 JAK2 inhibitor
- Known as:
- BMS-911543 JAK2 suppressor
- Catalog number:
- a-1175
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- ActivBio Active Biochem
- Gene target:
- BMS-911543 JAK2 inhibitor
Related genes to: BMS-911543 JAK2 inhibitor
- Gene:
- JAK2 NIH gene
- Name:
- Janus kinase 2
- Previous symbol:
- -
- Synonyms:
- JTK10
- Chromosome:
- 9p24.1
- Locus Type:
- gene with protein product
- Date approved:
- 1992-04-16
- Date modifiied:
- 2019-04-23
Related products to: BMS-911543 JAK2 inhibitor
Related articles to: BMS-911543 JAK2 inhibitor
- Ovarian cancer (OC) is the most lethal gynecological malignancy. Human epididymis protein 4 (HE4) is a secreted glycoprotein serving as a clinical OC biomarker. This study aimed to employ RNAi technology to silence HE4 gene expression, combined with cisplatin (DDP), to explore the effects on the OVCAR-3 cell line and its cisplatin-resistant counterpart. - Source: PubMed
Publication date: 2026/08/10
Zuo YaxinWang RuiqinXu YunshuZhang XiaodanChen ChunhongGong YanlingYan MeixingHu Dan - The Alzheimer's Disease (AD) lacks effective disease-modifying therapy, even though amyloid-targeting immunotherapies have recently been applied clinically. N-methyl-D-Aspartate Receptors (NMDARs) play a central yet mechanistically complicated role in the pathophysiology of AD, where they are convergence points of amyloid-beta (Aβ) oligomer toxicity, tau-dependent excitotoxicity, and progressive synaptic failure. This critical review examines NMDAR dysfunction across the AD spectrum, with a focus on subunit-regulated signalling, subcellular localisation, and subsequent pathological cascades. The effects of Aβ oligomers on NMDAR activity involve multiple mechanisms that disrupt their function, including glutamate dysregulation mediated by GLT-1, redistribution of GluN2B to extrasynaptic areas, and inhibition of JAK2-CREB via activation of extrasynaptic receptors. Tau enhances excitotoxic injury throughdendritic mislocalization, and the tau-Fyn-GluN2B complex, which propels pro-death signalling by DAPK1. This conceptually important prevailing synaptic-extrasynaptic dichotomy is fiercely criticised here, given evidence that synaptic receptors containing GluN2A also mediate pathological signalling during sustained Aß exposure, and that tri-heteromeric receptor populations are problematic for subunit-selective targeting. Neuroinflammation, dysfunction of the blood-brain barrier, and excitotoxic amplification via GluN2C/D-enriched receptor pools in neurons, astrocytes, microglia, oligodendrocytes, and endothelial cells are underexplored therapeutic targets for neurodegenerative disease (non-neuronal NMDARs). Memantine is the only approved NMDAR-targeting agent for AD. Subunit-selective antagonists have not been translated into clinical use, and the positive allosteric modulator dalzanemdor (SAGE-718) did not pass its randomised Phase 2 trial in 2024. The most mechanistically justified approach is to advance subunit-selective, compartment-specific, or protein-complexdisrupting strategies. Although it is not established whether any single NMDAR-targeting intervention will suffice as a disease-modifying therapy, the convergence of molecular, genetic, and clinical evidence positions NMDAR dysfunction as a tractable , if therapeutically demanding , node in the AD pathogenic network, warranting continued, mechanism-informed drug discovery. - Source: PubMed
Publication date: 2026/08/13
Khan Md SirajuddinAshesh Astik ManjuMammen Mithul VAlhusaini AbdulrahmanJawaid TalhaAkhtar Md SayeedOrayj KhalidAnsari IsrarKumar DileepKumar Ajay - Lung cancer is the most common pulmonary malignancy. WHO data show that its incidence and mortality are rising globally, severely threatening public health. - Source: PubMed
Sun JiaJifu CiliQiu YanliLu LinxiaXu ZhenyuHe ZilinWang Jingtao - SHMT2 (serine hydroxymethyltransferase 2) is a pivotal enzyme in cellular metabolism and is closely associated with the initiation and progression of malignant tumors, garnering significant attention in cancer research and therapy. Aberrant expression of SHMT2 has been observed in various cancers, correlating with tumor aggressiveness and patient prognosis. Functionally, SHMT2 participates in one-carbon metabolism, supplying methyl donors and biosynthetic precursors to support tumor cell proliferation. Additionally, it modulates redox homeostasis, promoting cancer cell survival and progression. SHMT2 also interacts with key signaling pathways, including JAK2/STAT3 and Akt/mTOR, thereby influencing tumor cell growth, invasion, and metastasis. Further elucidation of the molecular mechanisms by which SHMT2 contributes to tumorigenesis may provide critical insights for precision diagnosis, targeted therapy, and prognostic evaluationin oncology. - Source: PubMed
Publication date: 2026/08/18
Li MeiXu Ya NanSu XiulanWen Jianxun - Cancer involves abnormal cell proliferation and migration throughout the body. Genetic changes occurring in hereditary breast cancer led to the activation of oncogenes, resulting in gain-of-function effects. This study was designed to conduct a phylogenetic analysis of breast cancer-related oncogenes and tumor suppressor genes families in humans relevant to different species and their potential against breast cancer. - Source: PubMed
Publication date: 2026/08/14
Nazir AmnaAmbreen SadafNawaz Yasir